XBI SPDR S&P Biotech ETF Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:00
Jul 17
Jul 17
Long biotech, defense, and quantum themes.
Biotech, defense, and quantum computing are multi-year themes that could benefit as AI implementation expands beyond pure tech.
LOW
22:54
Jul 15
Jul 15
Speaker flags Lilly negotiating a deal at a premium as a potential M&A catalyst for biotech sector; no explicit personal position stated.
LOW
14:07
Jul 15
Jul 15
Buy XBI as cold PPI/CPI reduce rate pressure on biotech, record M&A and capital raises signal sector health, and FDA cleanup provides regulatory tailwind; prior context adds $200 YE price target.
HIGH
22:04
Jul 14
Jul 14
New expansion broadening favors consumer, transports, biotech.
A new economic expansion following the ending of the rolling recession creates earnings broadening beyond AI beneficiaries. Consumer discretionary goods, transports, and biotech are the preferred ways to express this broadening because positioning and sentiment in these areas are still subdued, offering upside as the rotation accelerates.
HIGH
12:58
Jul 14
Jul 14
Buy XBI as below-consensus CPI print provides the rate-sensitive catalyst biotech needed to break to new all-time highs; author frames lower inflation as the key missing driver, though conviction is hedged.
MED
12:55
Jul 14
Jul 14
Buy XBI targeting $200 by year-end; thesis rests on accelerating M&A activity in biotech, the CPI-driven inflation relief reducing rate pressure on growth/biotech, and a catalyst-heavy second half pipeline.
MED
12:55
Jul 14
Jul 14
Buy XBI as accelerating M&A activity, a below-consensus CPI print easing rate pressure on biotech valuations, and a catalyst-dense H2 pipeline support a move toward $200 by year-end.
MED
14:22
Jul 10
Jul 10
The author references the XBI biotech index being down 4% but expresses no directional view, only a casual comparison to a tennis match.
LOW
06:00
Jul 10
Jul 10
Avoid Korean biotech, sell on rebounds.
The Korean biotech sector has lost market credibility due to repeated FDA setbacks (e.g., HLB's third rejection, Peptron's uncertainty). High uncertainty and low reward mean the sector is not participating in this rebound; sell on strength.
HIGH
18:02
Jul 09
Jul 09
Biotech seasonality suggests buying in May and holding through summer and fall has worked historically, but no current position is stated.
20:36
Jul 08
Jul 08
Biotech M&A and equity rally accelerating
Biotech M&A is booming in 2026, with more deals over $1 billion than all of 2025 combined, driven by large pharma facing $300 billion in patent cliffs by 2030 and being rewarded for acquisitions. A new class of mid-cap buyers has emerged, private transactions are surging, and equity markets have resurged (XBI up 80% YTD). Regulatory fears have flipped, creating a virtuous cycle of capital flowing into biotech.
HIGH
13:09
Jul 08
Jul 08
AI accelerates biotech drug discovery boom
AI is revolutionizing biotech by accelerating protein folding and drug simulations. With a $300 billion drug patent cliff coming, AI enhances the ability to create new products, diagnostics, and longevity solutions. The biotech sector is seeing liquidity and IPO activity as a result.
HIGH
21:53
Jul 06
Jul 06
Biotech attractive with falling rates, M&A
Biotech is one of the most rate-sensitive areas of the market and has historically done very well in falling rate regimes. With policy expectations too hawkish and the potential for lower rates, biotech offers an attractive risk-reward setup, particularly with an M&A cycle that continues to build.
MED
20:09
Jul 06
Jul 06
Author reflects on selling CRNX too soon before its Vertex acquisition, praises XBI strength, and maintains unchanged ABVX and NKTR positions while planning new long ideas and a potential short book.
LOW
20:08
Jul 06
Jul 06
The author congratulates CRNX longs on a premium deal and highlights Vertex and the biotech ETF as part of a broader bullish market observation, not a personal position.
LOW
19:42
Jul 06
Jul 06
Broadening trade reignites, shift to hyperscalers, biotech.
The broadening trade is reigniting as oil prices have declined and Fed rate hike fears have eased, leading to lower long-term rates. This environment supports a rotation away from concentrated semiconductor positions into other areas: hyperscalers (large-cap AI-driven tech), biotech, and consumer discretionary sectors. The market adjustment to a new Fed regime is creating wider dispersion but ultimately lower volatility, favoring a broader equity rally beyond just a few mega-cap names.
HIGH
13:08
Jul 06
Jul 06
The tweet highlights TD Cowen's key entities to watch in the biotech sector from July to September, referencing the XBI ETF as a broad sector proxy without expressing a personal position.
LOW
12:44
Jul 06
Jul 06
Author rhetorically asks whether to close their entire short book until new all-time highs, indicating uncertainty rather than a definitive position.
LOW
12:40
Jul 06
Jul 06
The author questions whether biotech's XBI index nearing its all-time high is a genuine breakout or a false signal, without stating a personal position.
LOW
07:00
Jul 04
Jul 04
Long US small caps, biotech, and industrials
Unlike the concentrated Korean market dominated by a few semiconductor names, the US market is broad-based and many other sectors are performing well. Lee specifically highlights that the Russell (small caps), biotech sector, and industrial sector in the US are all looking good right now, presenting an attractive investment opportunity in those US sectors.
MED
00:50
Jul 03
Jul 03
Cooling employment data favors pharma/bio growth stocks.
US bio stocks like J&J, AbbVie, and Vertex are hitting new highs. The domestic pharma/bio sector is likely to follow this upward trend, making it a good area to focus on while semiconductors rest.
MED
20:01
Jul 02
Jul 02
The tweet expresses excitement about these biotech tickers with no explicit position or directional call, so they are indexed as watch.
LOW
19:45
Jun 30
Jun 30
Record M&A and FDA changes boost biotech
Biotech is having a great run, supported by two very relevant factors: significant changes at the FDA that did not derail the group, and an unprecedented M&A tailwind that is virtually guaranteed to make this a record year for biotech M&A. Additional money flows have come from reduced enthusiasm for crypto and broader risk-asset appreciation.
HIGH
10:24
Jun 30
Jun 30
Author notes XBI up ~20% recently and frames it as a bull market backdrop for biotech; no personal position or directional commitment stated, used as benchmark context.
MED
11:30
Jun 29
Jun 29
Korean biotech top pick, gap narrowing
The Korean biotech and healthcare sector is the top pick within KOSDAQ. US biotech indices (XBI, NBI) are at all-time highs, while Korean biotech has decoupled and lagged. This gap will likely narrow, bringing foreign and institutional money. Additionally, US regulation on China’s CDMO, ADC, and dual-antibody firms will benefit Korean companies like LigaChem Bio, ABL Bio, and Orum Therapeutics, who have strong pipelines. Big-cap names like Samsung Biologics and Celltrion are globally profitable.
HIGH
02:27
Jun 29
Jun 29
Korean biotech to benefit from oil decline
Falling oil is historically a strong inverse driver for biotech. US biotech ETFs (XBI, IBB) are already breaking out to new highs, while Korean biotech has been deeply oversold and is just beginning to recover. With oil heading lower, Korean biotech equities are poised for a significant catch-up rally, supported by attractive valuations, the KOSDAQ promotion policy, and sector themes like obesity and ADC (antibody-drug conjugates).
HIGH
17:40
Jun 28
Jun 28
Author observes XBI outperforming with consistent sector inflows; no personal position disclosed, directional commentary only.
LOW
22:42
Jun 27
Jun 27
Buy biotech/genomics ETFs as a play on the 100% historical win rate for Healthcare in H2 of midterm election years; author explicitly endorses the seasonal rotation thesis with specific tickers.
MED
17:21
Jun 27
Jun 27
Author added XBI for a follower, noting its wild swings and high risk but mostly positive midterm returns, without stating a personal position.
05:35
Jun 27
Jun 27
The author provides a historical sector-by-sector performance guide for midterm election months, advising traders on timing cycles without stating any current positions or forward trade calls.
LOW
About XBI Analyst Coverage
Buzzberg tracks XBI (SPDR S&P Biotech ETF) across 22 sources. 55 bullish vs 2 bearish calls from 52 analysts. Sentiment: predominantly bullish (49%). 109 total trade ideas tracked. Past 7 days: 6 bullish, 1 watch. Latest voices: Mimi Duff, seedy19tron, Mike Wilson.